by Mybiogate | Nov 10, 2020 | Industry Research
Author: Ginger Ding “Reflections on CRISPR’s Potential (Part 1)” explores the bottlenecks and challenges of CRISPR clinical applications and uses the case study of CRISPR Therapeutics and Editas to interpret the corporate strategies of different... by Mybiogate | Nov 6, 2020 | Industry Research
Author: Youwen Dai In China, the rapid growth of the analgesic market is second only to oncology drugs. As an example, Yangtze River’s dezocine is an analgesic acting as a κ partial agonist and μ partial agonist. It leads the analgesics market in... by Mybiogate | Nov 5, 2020 | Industry Research
Author: CHEN Lixing Schizophrenia, as defined by the NIH National Institute of Mental Health, is a “mental disorder characterized by disruptions in thought processes, perceptions, emotional responsiveness, and social interactions.” Symptoms of schizophrenia can... by Mybiogate | Nov 4, 2020 | Chinese company profile
China Resources Pharmaceutical Group Ltd. (CR Pharma) 2019 Revenue: US$ 26.4 Billion Number of Employees: 54,000 Founded: 2007 Overview China Resources Pharmaceutical Group is the flagship subsidiary of China Resources Group (Ranks 79 on the 2020 Fortune Global 500... by Mybiogate | Nov 3, 2020 | Industry Research
Author: Ginger Ding On October 7, 2020, the high-profile 2020 Nobel Prize in Chemistry was announced. Emmanuelle Charpentier and Jennifer A. Doudna won the award for their discovery of CRISPR/Cas9, so called genetic scissors. CRISPR is a gene editing tool that...